Home › Funds › Royalty Pharma Sub-Manager, LLC › CYTK

Royalty Pharma Sub-Manager, LLC position in CYTK

CYTOKINETICS INC · Health Care

Royalty Pharma Sub-Manager, LLC reported holding 980,392 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$64.6M, representing 32.92% of its reported portfolio and ranking #1 among its reported holdings. Royalty Pharma Sub-Manager, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)980.39K sh
Reported value held$64.62M
Portfolio Weight32.92%
First reportedQ4 2025
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Royalty Pharma Sub-Manager, LLC's CYTK position evolved

Royalty Pharma Sub-Manager, LLC first disclosed a stake in CYTK in Q4 2025 at 980,392 shares (US$62.3M). The position peaked in Q2 2026 at 980,392 shares, worth US$83.5M. Across 4 filings, Royalty Pharma Sub-Manager, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 980,392 shares valued at US$64.6M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 980.39K $62.29M New
Q1 2026 980.39K $64.62M Hold
Q2 2026 980.39K $83.52M Hold
Q3 2026 980.39K $64.62M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC) is a Health Care company. 42 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has Royalty Pharma Sub-Manager, LLC held CYTK?

Royalty Pharma Sub-Manager, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Royalty Pharma Sub-Manager, LLC's current position in CYTK?

As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 980.39K shares of CYTK (CYTOKINETICS INC), valued at $64.62M, representing 32.92% of its reported portfolio and ranking #1.

Has Royalty Pharma Sub-Manager, LLC been buying or selling CYTK?

In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in CYTK. The position peaked in Q2 2026 at 980.39K shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.